Gross Profit Trends Compared: United Therapeutics Corporation vs Vericel Corporation

Biotech Giants: A Decade of Profit Growth Compared

__timestampUnited Therapeutics CorporationVericel Corporation
Wednesday, January 1, 2014116263600011503000
Thursday, January 1, 2015139672500024698000
Friday, January 1, 2016152610000026076000
Sunday, January 1, 2017161960000033570000
Monday, January 1, 2018142910000058697000
Tuesday, January 1, 2019133120000080279000
Wednesday, January 1, 2020137520000084228000
Friday, January 1, 20211563000000106025000
Saturday, January 1, 20221789600000109788000
Sunday, January 1, 20232070000000135576000
Loading chart...

Igniting the spark of knowledge

A Tale of Two Biotechs: Profitability Trends from 2014 to 2023

In the competitive world of biotechnology, financial performance is a key indicator of a company's success. Over the past decade, United Therapeutics Corporation and Vericel Corporation have shown contrasting trends in their gross profit margins. United Therapeutics has consistently demonstrated robust growth, with a remarkable 78% increase in gross profit from 2014 to 2023. This growth underscores their strategic prowess in the biotech sector. In contrast, Vericel Corporation, while starting from a smaller base, has shown a significant upward trajectory, with gross profits increasing by over 1,000% during the same period. This impressive growth highlights Vericel's potential and resilience in a rapidly evolving market. As we look to the future, these trends offer valuable insights into the strategic directions and market positions of these two biotech giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025